Featured stories
- 14/11/24 LEO Pharma’s Anzupgo® (delgocitinib) Cream Achieves Marketing Approval in Switzerland
- 07/11/24 LEO Pharma gears for growth with senior leadership changes
- 31/10/24 LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
- 11/10/24 LEO Pharma commits to net-zero greenhouse gas emissions by 2050
- 26/08/24 LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year
- 21/08/24 Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis
- 31/07/24 Change in the Board of Directors of LEO Pharma
- 04/07/24 LEO Pharma announces changes to its Global Leadership Team
- 01/06/24 Recognized professor joins LEO Pharma to accelerate external innovation
- 03/05/24 Solid start to the year: 13% revenue growth driven by strong performance in dermatology
- 29/02/24 LEO Pharma announces annual results 2023
- 23/01/24 LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals.
- 09/10/23 Globally known professor and dermatologist joins LEO Pharma
- 12/09/23 LEO Pharma delivers solid first half-year results and strengthens its capital structure
- 28/08/23 LEO Pharma announces changes to its Global Leadership Team
- 21/08/23 LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical
- 20/06/23 LEO Pharma announces changes to its Global Leadership Team
- 14/03/23 LEO Pharma adds internationally recognized dermatologist to Global Leadership Team
- 10/03/23 LEO Pharma and ICON enter a Strategic Partnership to propel clinical trial execution within medical dermatology
- 09/03/23 LEO Pharma announces annual results 2022
- 12/01/23 Delivering a financial turnaround of LEO Pharma
- 31/08/22 LEO Pharma appoints Paul Navarre new member of its Board of Directors
- 18/08/22 LEO Pharma appoints new Chief Financial Officer and Executive Vice President
- 03/08/22 LEO Pharma appoints new Executive Vice President of Global Product Supply
- 28/06/22 LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
- 02/06/22 LEO Pharma strengthens its commercial organization
- 21/04/22 LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
- 17/03/22 LEO Pharma announces annual results 2021
- 17/02/22 LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States
- 31/01/22 LEO Pharma appoints Christophe Bourdon as new CEO
- 19/01/22 LEO Pharma introduces new operating model to increase competitiveness and support future growth
- 05/01/22 LEO Pharma convene dermatology experts in global initiative on skin health
- 30/11/21 Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
- 15/11/21 LEO Pharma successfully refinances loan facility
- 29/09/21 LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
- 06/07/21 LEO Pharma and X-Chem Enter Into Discovery Research Agreement
- 22/03/21 LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
- 15/12/20 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
- 27/10/20 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
- 22/09/20 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
- 30/08/20 LEO Pharma sells portfolio of four products to Cheplapharm
- 19/08/20 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
- 18/08/20 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
- 29/06/20 LEO Pharma strengthens global leadership team
- 12/03/20 Updates regarding COVID-19
- 20/11/19 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- 18/11/19 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 13/11/19 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- 06/11/19 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- 29/10/19 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- 23/10/19 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- 30/06/19 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- 02/06/19 LEO Pharma appoints Catherine Mazzacco as new CEO
- 09/05/19 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- 10/04/19 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- 08/04/19 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- 18/03/19 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
Follow us on social media
Our performance and results
LEO Pharma's Annual Report covers our financial and sustainability reporting for the financial year from January 1 to December 31.
Read our 2023 Annual ReportOur press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request.. For updated information about clinical trials, please visit https://clinicaltrials.gov/ https://clinicaltrials.gov/.
MEDIA INQUIRIES
